Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation

Nature Medicine

Volumn 10, Issue 11, 2004, Pages 1222-1226

  Girardi, Guillermina ^a   Redecha, Patricia ^a   Salmon, Jane E ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; IMMUNOGLOBULIN G; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FEMALE; FETUS WASTAGE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; SPONTANEOUS ABORTION; THROMBOSIS;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BLOTTING, WESTERN; CHROMATOGRAPHY, AFFINITY; COMPLEMENT ACTIVATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FETAL DEATH; HEPARIN; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; PREGNANCY;

ANIMALIA;

EID: 9144243607     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1121     Document Type: Article

References (39)

1. Wilson, W.A. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42, 1309-1311 (1999).
2. Lockshin, M.D., Sammaritano, L.R. & Schwartzman, S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum. 43, 440-443 (2000).
3. Levine, J.S., Branch, D.W. & Rauch, J. The antiphospholipid syndrome. N. Engl. J. Med. 346, 752-763 (2002).
4. Branch, D.W. et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am. J. Obstet. Gynecol. 163, 210-216 (1990).
5. Blank, M., Cohen, J., Toder, V. & Shoenfeld, Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc. Natl. Acad. Sci. USA 88, 3069-3073 (1991).
6. Simantov, R. et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J. Clin. Invest. 96, 2211-2219 (1995).
7. Piona, A. et al. Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice. Scand. J. Immunol. 41, 427-432 (1995).
8. Pierangeli, S.S. et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 99, 1997-2002 (1999).
9. Holers, V.M. et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med. 195, 211-220 (2002).
10. Girardi, G. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112, 1644-1654 (2003).
11. Derksen, R.H., Khamashta, M.A. & Branch, D.W. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum. 50, 1028-1039 (2004).
12. Out, H.J., Kooijman, C.D., Bruinse, H.W. & Derksen, R.H. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur. J. Obstet. Gynecol. Reprod. Biol. 41, 179-186 (1991).
13. Magid, M.S. et al. Placental pathology in systemic lupus erythematosus: a prospective study. Am. J. Obstet. Gynecol. 179, 226-234 (1998).
14. Ecker, E. & Gross, P. Anticomplementary power of heparin. J. Infect. Dis. 44, 250 (1929).
15. Ecker, E. & Pillemer, L. Anti-coagulants and complementary activity: an experimental study. J. Immunol. 40, 73 (1941).
16. Baker, P.J., Lint, T.F., McLeod, B.C., Behrends, C.L. & Gewurz, H. Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis polyanions and polycations. J. Immunol. 114, 554-558 (1975).
17. Loos, M., Volanakis, J.E. & Stroud, R.M. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement-III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry 13, 789-791 (1976).
18. Rent, R., Myhrman, R., Fiedel, B.A. & Gewurz, H. Potentiation of C1-esterase inhibitor activity by heparin. Clin. Exp. Immunol. 23, 264-271 (1976).
19. Weiler, J.M., Yurt, R.W., Fearon, D.T. & Austen, K.F. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J. Exp. Med. 147, 409-421 (1978).
20. Kazatchkine, M.D., Fearon, D.T., Metcalfe, D.D., Rosenberg, R.D. & Austen, K.F. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J. Clin. Invest. 67, 223-228 (1981).
21. Edens, R.E., Linhardt, R.J., Bell, C.S. & Weiler, J.M. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacology 27, 145-153 (1994).
22. Ninomiya, H., Kawashima, Y. & Nagasawa, T. Inhibition of complement-mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low-molecular weight heparin. Br. J. Haematol. 109, 875-881 (2000).
23. Mollnes, T.E. et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100, 1869-1877 (2002).
24. Wetsel, R.A., Kildsgaard, J. & Haviland, D.L. Complement anaphylatoxins (C3a, C4a, C5a) and their receptors (C3aR, C5aR/CD88) as therapeutic targets in inflammation. in Therapeutic Interventions in the Complement System, Vol. 9 (eds. Lambris, J.D. & Holers, V.M.) 113-153 (Humana Press, Totowa, NJ, 2000).
25. Di Simone, N. et al. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Hum. Reprod. 12, 2061-2065 (1997).
26. Franklin, R.D. & Kutteh, W.H. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet. Gynecol. 101, 455-462 (2003).
27. Wagenknecht, D.R. & McIntyre, J.A. Interaction of heparin with beta 2-glycoprotein I and antiphospholipid antibodies in vitro. Thromb. Res. 68, 495-500 (1992).
28. Di Simone, N. et al. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum. Reprod. 14, 489-495 (1999).
29. Friedrichs, G.S., Kilgore, K.S., Manley, P.J., Gralinski, M.R. & Lucchesi, B.R. Effects of heparin and N-acetyl heparin on ischemia/reperfusion- induced alterations in myocardial function in the rabbit isolated heart. Circ. Res. 75, 701-710 (1994).
30. Koenig, A., Norgard-Sumnicht, K., Linhardt, R. & Varki, A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J. Clin. Invest. 101, 877-889 (1998).
31. Wang, L., Brown, J.R., Varki, A. & Esko, J.D. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J. Clin. Invest. 110, 127-136 (2002).
32. Rops, A.L et al. Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int. 65, 768-785 (2004).
33. Hirsh, J. et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 119, 64S-94S (2001).
34. Menon, V., Berkowitz, S.D., Antman, E.M., Fuchs, R.M. & Hochman, J.S. New heparin dosing recommendations for patients with acute coronary syndromes. Am. J. Med. 110, 641-650 (2001).
35. Ikematsu, W. et al. Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice. Arthritis Rheum. 41, 1026-1039 (1998).
36. Salmon, J.E., Millard, S.S., Brogle, N.L. & Kimberly, R.P. Fc gamma receptor IIIb enhances Fc gamma receptor IIa function in an oxidant-dependent and allele-sensitive manner. J. Clin. Invest. 95, 2877-2885 (1995).
37. Gu, J.M. et al. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J. Biol. Chem. 277, 43335-43343 (2002).
38. Gutierrez, G. et al. Regulation of interleukin-6 fetoplacental levels could be involved in the protective effect of low-molecular weight heparin treatment on murine spontaneous abortion. Am. J. Reprod. Immunol. 51, 160-165 (2004).
39. Rote, N.S., Vogt, E., DeVere, G., Obringer, A.R. & Ng, A.K. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome. Am. J. Reprod. Immunol. 39, 125-136 (1998).